Skip to content

To determine whether smartphone and internet assisted self-management tools can help improve medication adherence in patients with Parkinson's disease

A randomised controlled trial to evaluate the impact of SMARTphone and Internet assisted self-management and adherence tools to manage Parkinson?s Disease (PD): the SMART-PD trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN45824264
Enrollment
266
Registered
2013-11-05
Start date
2014-01-01
Completion date
Unknown
Last updated
2018-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease Nervous System Diseases Parkinson disease

Interventions

For patients A mobile app which consists of: 1. A self-tracking interface 2. A reminder system that gives alerts and helps track medication intake 3. Games to track physical and cognitive responsiven

Sponsors

uMotif Limited (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults aged 21-75 years or over diagnosed with, or with probable, idiopathic PD 2. Prescribed one or more anti-parkinsonian medications by a consultant neurologist or consultant physician or GP with specialist knowledge of movement disorders 3. English speaking and literate i.e can read, write, and speak in English and compute and solve problems at levels of proficiency necessary to function daily at job and/or daily living 4. Has access to a smartphone and/or internet on a regular (> weekly) basis in their home 5. Stable medication regime i.e. not altered within the previous month and not expected to change during the period of the trial (16 weeks) 6. Not diagnosed with dementia or significant cognitive impairment

Exclusion criteria

Exclusion criteria: 1. Suspected Parkinsonism due to other causes than idiopathic PD 2. Treated with anti-parkinsonian medications (anti-cholinergics) for side effects of prolonged neuroleptic treatment 3. Diagnosed with dementia or significant cognitive impairment 4. Diagnosed with mental illness associated with psychosis ? schizophrenia, severe depression with psychosis, bipolar affective disorder 5. Detrimental illness with a short life expectancy

Design outcomes

Primary

MeasureTime frame
Adherence to medication determined by Morisky Medication Adherence Scale (MMAS-8) at 16 weeks

Secondary

MeasureTime frame
1. QoL determined by the Parkinson?s Disease Questionnaire-39 (PDQ-39) 2. Quality of consultation for PD patients (questions from Patient-Centered Questionnaire for Parkinson?s Disease [PCQ-PD]) 3. Non Motor Symptoms Questionnaire (NMSQuest) 4. Hospital Anxiety and Depression rating scale 5. Beliefs about Medication Questionnaire (BMQ)

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 7, 2026